Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology Company
04 Junio 2014 - 1:27AM
Company Announcement
- Research collaboration with an undisclosed large
Biotechnology company for DuoBody(R) and HexaBodyTM technology
platforms
- Genmab's first HexaBody collaboration
Genmab A/S (Copenhagen:GEN), together with
its subsidiary, Genmab B.V., announced today a research
collaboration with an undisclosed Biotechnology company which would
use and evaluate Genmab's proprietary antibody technologies, the
DuoBody and HexaBody platforms.
"We are enthusiastic to enter our first research collaboration
for the HexaBody technology which was unveiled just over a year
ago. This exciting technology has the potential to enhance
antibody efficacy in a fundamentally new way. We are also very
pleased to enter another DuoBody platform collaboration and we look
forward to exploring the therapeutic potential of products
incorporating the HexaBody and DuoBody technologies with this major
Biotechnology company," said Jan van de Winkel, Ph.D., Chief
Executive Officer of Genmab.
The financial terms of the agreement have not been
disclosed. This agreement will not have a material impact on
Genmab's financial results and cash position.
About the DuoBody Platform The DuoBody platform
is an innovative platform for the discovery and development of
bispecific antibodies that may improve antibody therapy of cancer,
autoimmune, infectious and central nervous system disease.
Bispecific antibodies bind to two different epitopes either on the
same, or on different targets (also known as dual-targeting) which
may improve the antibodies' specificity and efficacy in
inactivating the disease targets. DuoBody molecules are unique in
combining the benefits of bispecificity with the strengths of
conventional antibodies which allows DuoBody molecules to be
administered and dosed as other antibody therapeutics. Genmab's
DuoBody platform generates bispecific antibodies via a fast and
broadly applicable process which is easily performed at standard
bench, as well as commercial, manufacturing scale.
About HexaBody technology HexaBody technology,
a broadly applicable antibody platform from Genmab, allows for the
creation of potent therapeutics by inducing antibody hexamer
formation (clusters of six antibodies). The HexaBody platform
builds on natural antibody biology and enhances complement-mediated
killing (complement-dependent cytotoxicity (CDC)), allowing
antibodies with limited or absent CDC to be transformed into potent
cytotoxic antibodies. The HexaBody technology creates
opportunities to explore new product candidates, to repurpose drug
candidates unsuccessful in previous clinical trials due to
insufficient potency and may provide a useful strategy in product
life cycle extension. The HexaBody technology can be directed to
any antigen or target, including those implicated in cancer and
infectious diseases. The HexaBody technology can be combined with
Genmab's DuoBody platform as well as other antibody
technologies.
About Genmab A/S Genmab is a publicly traded,
international biotechnology company specializing in the creation
and development of differentiated human antibody therapeutics for
the treatment of cancer. Founded in 1999, the company
currently has one marketed antibody, Arzerra(R) (ofatumumab) for
the treatment of certain chronic lymphocytic leukemia indications,
a clinical pipeline with both late and early stage programs, and an
innovative preclinical pipeline. Genmab's technology base
consists of validated and proprietary next generation antibody
technologies - the DuoBody platform for generation of bispecific
antibodies, and the HexaBody platform which creates effector
function enhanced antibodies. Genmab's deep antibody
expertise is expected to provide a stream of future product
candidates. Partnering of selected innovative product
candidates and technologies is a key focus of Genmab's strategy and
the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit
www.genmab.com
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations
& Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E:
r.gravesen@genmab.com This Company Announcement contains forward
looking statements. The words "believe", "expect", "anticipate",
"intend" and "plan" and similar expressions identify forward
looking statements. Actual results or performance may differ
materially from any future results or performance expressed or
implied by such statements. The important factors that could cause
our actual results or performance to differ materially include,
among others, risks associated with pre-clinical and clinical
development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market
acceptance of our products, our inability to manage growth, the
competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion
of these risks, please refer to the risk management sections in
Genmab's most recent financial reports, which are available on
www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements in relation to actual results,
unless required by law. Genmab A/S and its subsidiaries own the
following trademarks: Genmab(R); the Y-shaped Genmab logo(R);
Genmab in combination with the Y-shaped Genmab logoTM; the DuoBody
logoTM; HuMax(R); HuMax-CD20(R); DuoBody(R), HexaBodyTM and
UniBody(R). Arzerra(R) is a registered trademark of
GlaxoSmithKline.
Company Announcement no. 30 CVR no. 2102 3884
Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark
Genmab A S (PK) (USOTC:GNMSF)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genmab A S (PK) (USOTC:GNMSF)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024